Onride

Ondansetron Hydrochloride Dihydrate USP

Composition

Onride tablet: Each film coated tablet contains Ondansetron Hydrochloride Dihydrate USP equivalent to Ondansetron 8 mg.

Onride oral solution: Each 5 ml oral solution contains Ondansetron Hydrochloride Dihydrate USP equivalent to Ondansetron 4 mg.

Pharmacology

Ondansetron (**Onride**) is a selective 5HT3 receptor antagonist. While its mechanism of action has not been fully characterized, Ondansetron (**Onride**) is not a dopamine-receptor antagonist. Ondansetron (**Onride**) is well absorbed from the gastrointestinal tract and undergoes some first-pass metabolism.

Indications

- Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy
- Prevention of nausea and vomiting associated with radiotherapy
- Prevention of post-operative nausea and vomiting
- Nausea-vomiting associated with pregnancy
- Nausea-vomiting associated with gastroenteritis

Dosage & Administration

Prevention of chemotherapy induced nausea & vomiting (CINV):

Adult-Tablet and oral solution: The recommended adult oral dosage of **Onride** (Ondansetron) is 24 mg given as three 8 mg tablets in highly emetogenic chemotherapy. In case of moderately emetogenic chemotherapy the oral dose is one 8 mg **Onride** (Ondansetron) tablet or 10 ml of **Onride** (Ondansetron) oral solution given twice daily.

Pediatric patients-Tablet and oral solution: for pediatric patients 4 through 11 years of age the dosage is one 4 mg **Onride** tablet or 5ml of **Onride** solution should be administered 3 times a day for 1 to 2 days after completion of chemotherapy.

Radiotherapy induced nausea and vomiting:

Adult-Tablet and oral solution: the recommended oral dosage is one 8mg **Onride** tablet or 10ml of **Onride** oral solution given 3 times daily.

Post-operative nausea & vomiting (PONV):

Adult-Tablet and oral solution: the recommended dosage is 16 mg given as two 8 mg **Onride** tablets or 20 ml of **Onride** oral solution 1hour before induction of anesthesia.

Dosage adjustment for patients with impaired hepatic function-

Tablet and oral solution: The total daily dose of 8 mg should not be exceeded.

Contraindications

Ondansetron is contraindicated in patients with known hypersensitivity to the drug.

Warning & Precautions

Hypersensitivity reactions have been reported in patients who have exhibited hyper sensitivity to other 5-HT3 receptor antagonists.

Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

Side Effects

Generally Ondansetron is well tolerated. However few side effects including headache, diarrhoea, fatigue, dizziness and constipation may be seen after Ondansetron is administered.

Use in pregnancy & Lactations

Pregnancy: Pregnancy category B.

Nursing mother: It is not known whether Ondansetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ondansetron is administered to a nursing woman.

Drug Interactions

The following drugs should be used with caution when concomitantly used with Ondansetron: Phenytoin, Carbamazepine, Rifampicin & Tramadol.

Storage

Store in a cool and dry place (below 30^0 C), protected from light & moisture.

Packing:

Onride tablet: Each box contains 3x10 tablets in blister pack.

Onride oral solution: Each bottle contains 50 ml solution in pet bottle.

Manufactured by:

MEDICON

MEDICON Pharmaceuticals Ltd.
Mirpur, Dhaka, Bangladesh

ক্যালফিল-ও

(K¨vjwmqvg I‡iv‡UU)
U¨ve‡jU

Dcv`vb

K¨vjwdj- I U¨ve‡jUt cÖwZwU wdj¥-‡Kv‡UW U¨ve‡jU G i‡q‡Q K¨vjwmqvg I‡iv‡UU WvBnvB‡Wª U AvBGbGb hv K¨vjwmqvg I‡iv‡UU 740 wg.MÖv. Gi mgZ~j¨|

dvg©v‡KvjwR

K¨vjwdj-I (K¨vjwmqvg I‡iv‡UU) G i‡q‡Q K¨vjwmqvg I‡iv‡UU hv GKwU K¨vjwmqvg m¤ú~iK Ges Gi mv‡_ GKwU Kvh©Kix A¨vgvB‡bv Gwm‡Wi wP‡jwUs wjM¨vÛ I‡ivwUK GwmW i‡q‡Q| I‡ivwUK GwmW †mjyjvi †gg‡eª‡bi ga¨ w`‡q K¨vjwmqvg cwien‡b mvnvh¨ K‡i d‡j B›Uª v‡mjyjvi we‡kl K‡i nv‡o K¨vjwmqv‡gi ch©vßZvq mvnvh¨ K‡i| K¨vjwmqvg I‡iv‡UU my¯’ KvwU©‡jR iÿ‡bI mvnvh¨ K‡i| GQvovI I‡iv‡UU wWGbG Ges AviGbG ^Zwi‡Z mnvqZv K‡i| K¨vjwmqvg I‡iv‡UU RwUj †mj‡gg‡eª‡bi ga¨ w`‡q hvIqvi mvg_©¨ Av‡Q hv‡Z GwUi wecvK KvwU©‡j‡R NU‡Z cv‡i|

wb‡`©kbv

Aw÷Ic‡ivwmm, Aw÷Ig¨vjvwmqv, wi‡KUm, nvB‡cvc¨viv_vBiqwWRg, Mf©ve¯’v I `y»`vbKvjxb Ae¯’vq, cÖme cieZx© mZK©Zvq, ‡g‡bvcR cieZ©x Ges cðvw`‡Ki wb‡Pi As‡ki e¨v_vq wb‡`©wkZ| †mebwewa Ges ‡mebgvÎv w`‡b 1-2 wU U¨ve‡jU Lvev‡ii mv‡_ ‡meb Ki‡Z n‡e| A_ev wPwKrm‡Ki civgk© Abyhvqx †me¨|

cÖwZwb‡`©kbv

Ily‡ai †h †Kvb Dcv`v‡bi cÖwZ AwZms‡e`bkxjZv ev nvBcviK¨vjwmwgqv‡Z cÖwZwb‡`©wkZ|

mZK©Zv I mveavbZv t

‡ivMxi hw` K¨vjwmqvg I‡iv‡UU Gi cÖwZ GjvwR© _v‡K Zvn‡j mZK©Zv Aej¤^b Ki‡Z n‡e| Lvev‡ii mv‡_ K¨vjwmqvg MÖnb bv Ki‡j wKWwb‡Z cv_i nevi SuywK †e‡o hvq| AZGe K¨vjwmqvg I‡iv‡UU Lvev‡ii mv‡_ MÖnb Kiv DwPZ|

cvk¦©cÖwZwµqv

K¨vjwmqvg I‡iv‡UU mvavibZ mymnbxq| K¨vjwmqvg I‡iv‡UU Gi cÖavb cvk¦©cÖwZwµqvi g‡a¨ i‡q‡Q Zj‡cU dz‡j hvIqv| gv‡S gv‡S ÿzavg›`v, †KvôKvwVb¨, ewg ewg fve, ewg, A¯^vfvweK IRb Kgv, gv_ve¨_v, Z…òv e„w×, Nb Nb cÖme, wKWbx‡Z cv_i n‡Z cv‡i|

Mfv©e¯’vq I ¯Íb¨`vbKv‡j e¨envi

‡h me gwnjv Mf©eZx Ges ev”Pv‡`i `ya cvb Kivb Zv‡`i †ekx cwigvb K¨vjwmqvg `iKvi nq| †cÖM‡bwÝ m¤úwK©Z D”Pi³Pvc gwnjv I Zv‡`i ev”Pvi Rb¨ GKwU mvaviY I gvivZ¥K SzuwK Ges K¨vjwmqvg I‡iv‡UU GB ai‡bi SzuwK Kgv‡Z mvnvh¨ K‡i|

Ab¨vb¨ Ily‡ai mv‡_ wµqv

K¨vjwmqvg Ab¨vb¨ Jla †hgb wemdm‡dv‡bU (A¨v‡jb‡Wªv‡bU, wi‡mWª‡bU), †UUªvmvBwK¬b Gw›Uev‡qvwUK (Ww·mvBwK¬b, wg‡bvmvBwK¬b), KzB‡bv‡jvb Gw›Uev‡qvwUK (wm‡cÖvd¬·vwmb, wj‡fvd¬·vwmb) Gi †kvlb Kwg‡q ‡`q|

msi¶Yt

Av‡jv I Av`«©Zv †_‡K `~‡i,VvÛv I ïK&‡bv ¯’v‡b (30◦‡mt Gi wb‡P) ivLyb| mKj Ilya wkï‡`i bvMv‡ji evB‡i ivLyb|

Ily‡ai mieivn

K¨vjwdj- I U¨ve‡jUt cÖwZ ev‡· 3× 10 wU U¨ve‡jU weø÷vi w÷ª‡c mieivn Kiv nq|